Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00022048
Status:
COMPLETED
Last Update Posted:
2013-05-15
First Post:
2001-08-10
Brief Title:
Bevacizumab in Treating Patients With Myelodysplastic Syndrome
Sponsor:
Stanford University
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| MyelodysplasticMyeloproliferative Neoplasms |
| Leukemia |
| Myelodysplastic Syndromes |
Keywords:
| Name | View |
|---|---|
| refractory anemia | View |
| refractory anemia with ringed sideroblasts | View |
| refractory anemia with excess blasts | View |
| refractory anemia with excess blasts in transformation | View |
| chronic myelomonocytic leukemia | View |
| de novo myelodysplastic syndromes | View |
| previously treated myelodysplastic syndromes | View |
| myelodysplasticmyeloproliferative neoplasm unclassifiable | View |
| atypical chronic myeloid leukemia BCR-ABL1 negative | View |